Results 21 to 30 of about 1,060,485 (284)

A computational model for the evaluation of complement system regulation under homeostasis, disease, and drug intervention. [PDF]

open access: yesPLoS ONE, 2018
The complement system is an intricate defense network that rapidly removes invading pathogens. Although many complement regulators are present to protect host cells under homeostasis, the impairment of Factor H (FH) regulatory mechanism has been ...
Nehemiah Zewde, Dimitrios Morikis
doaj   +1 more source

Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition

open access: yesBMC Nephrology, 2023
Background Thrombotic microangiopathy (TMA) is a potentially organ and life-threatening condition affecting patients with multiple myeloma (MM). Cases of proteasome inhibitor-induced TMA and specifically carfilzomib-induced TMA have been rarely reported ...
Lorenzo Catanese   +2 more
doaj   +1 more source

Ornithodoros moubata Complement Inhibitor Is an Equally Effective C5 Inhibitor in Pigs and Humans [PDF]

open access: yesThe Journal of Immunology, 2011
Abstract Experimental evidence suggests that C inhibition and more particularly combined inhibition of C and the TLR coreceptor CD14 may be of therapeutic benefit in sepsis and other inflammatory conditions. A barrier to the testing and further development of many inhibitors is that their activity is species specific.
Barratt-Due, Andreas   +7 more
openaire   +3 more sources

Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria

open access: yesTherapeutic Advances in Hematology, 2022
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, hematologic disease characterized by complement-mediated hemolysis, thrombosis, and various degrees of bone marrow dysfunction.
Raymond S.M. Wong
doaj   +1 more source

Thrombosis and paroxysmal nocturnal haemoglobinuria

open access: yesThrombosis Update, 2021
Thrombosis is the most common, most feared complication of paroxysmal nocturnal haemoglobinuria (PNH), a striking example of the effect of uncontrolled complement activation and haemolysis on vascular biology and haemostasis.
Jean-Christophe Gris   +6 more
doaj   +1 more source

Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis [PDF]

open access: yesExpert Opinion on Investigational Drugs, 2021
Generalized myasthenia gravis (gMG) is an autoimmune disorder in which pathogenic autoantibodies damage the neuromuscular junction, causing disabling or life-threatening muscle weakness. Most treatments nonspecifically inhibit aspects of the immune system, do not directly address the causal mechanisms of tissue damage, and often have side-effect ...
Howard, James F.   +8 more
openaire   +4 more sources

Borrelia valaisiana resist complement-mediated killing independently of the recruitment of immune regulators and inactivation of complement components [PDF]

open access: yes, 2013
Spirochetes belonging to the Borrelia (B.) burgdorferi sensu lato complex differ in their resistance to complement-mediated killing, particularly in regard to human serum.
Christine Skerka   +24 more
core   +1 more source

Contribution of the infection-associated complement regulator-acquiring surface protein 4 (ErpC) to complement resistance of Borrelia burgdorferi [PDF]

open access: yes, 2012
Borrelia burgdorferi evades complement-mediated killing by interacting with complement regulators through distinct complement regulator-acquiring surface proteins (CRASPs).
Teresia Hallström   +14 more
core   +1 more source

Complement factor H-related proteins CFHR2 and CFHR5 represent novel ligands for the infection-associated CRASP proteins of Borrelia burgdorferi [PDF]

open access: yes, 2010
Background: One virulence property of Borrelia burgdorferi is its resistance to innate immunity, in particular to complement-mediated killing. Serum-resistant B.
Teresia Hallström   +34 more
core   +2 more sources

Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

open access: yesHaematologica, 2020
Eculizumab is first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH); however, approximately 11%-27% of patients may experience breakthrough hemolysis (BTH) on approved doses of eculizumab.
Robert A. Brodsky   +17 more
doaj   +1 more source

Home - About - Disclaimer - Privacy